Rome foundation endpoints and outcomes conference 2009: Optimizing clinical trials in FGID

American Journal of Gastroenterology

Volumn 105, Issue 4, 2010, Pages 722-730

  Chang, Lin ^a   Drossman, Douglas A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CISAPRIDE; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; GASTRIC DYSMOTILITY; HEALTH BEHAVIOR; HUMAN; ITALY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH PARESIS;

CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; GASTROINTESTINAL DISEASES; GUIDELINES AS TOPIC; HUMANS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77950490403     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.49     Document Type: Review

References (25)

1. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-1284
2. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130:1480-1491
3. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479
4. US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures\Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD, 2009.
5. Whitehead WE, Corazziari E, Prizont R et al. Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. Gut 1999;45(Suppl 2):II78-9.
6. Spiegel B, Camilleri M, Bolus R et al. Psychometric evaluation of patientreported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 2009;137:1944-1953, e1-3.
7. Labus J, Bolus R, Chang L et al. The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004;20:89-97.
8. Matsueda K, Harasawa S, Hongo M et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-235
9. Matsueda K, Hongo M, Tack J et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia\100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010; e-pub ahead of print 5 January 2010.
10. Fehnel S, Johnston J, Kurtz C, Mangel A. Assessing global change and symptom severity in subjects with IBS: qualitative item testing [abstr]. Am J Gastroenterol 2006;101:S483.
11. Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-1551
12. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415
13. Chang L. The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil 2008;20(Suppl 1):130-138
14. Lacy B, Everhart K, Weiser K, De Lee R et al. Medication risk taking behavior in IBS patients [abstr]. Am J Gastroenterol 2009;104:S489.
15. Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009;43:541-550
16. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005;3:717-725 (Pubitemid 41116722)
17. Drossman DA, Li Z, Toner NE et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995;40:986-995
18. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
19. Drossman DA, Chang L, Schneck S et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci 2009;54:1532-1541
20. Patrick DL, Drossman DA, Frederick IO et al. Quality of life in persons with irritable bowel syndrome. Development and validation of a new measure. Dig Dis Sci 1998;43:400-411
21. Spiegel B, Strickland A, Naliboff BD et al. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008;103:2536-2543
22. Rasquin A, Di Lorenzo C, Forbes D et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006;130:1527-1537
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370
24. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258-266
25. Revicki DA, Camilleri M, Kuo B et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment Pharmacol Ther 2009;30:670-680